Skip to content
Clinical Trials – home
GreeceBack to Greece

Clinical trials in Peristeri – page 28

1 033 clinical trials in Peristeri, Greece. Every trial is listed in the EU Clinical Trials Register and updated daily.

GreeceOur site in GreeceΚλινικεσΔοκιμεσ.gr(opens in a new tab)
Peristeri at a glance
1 033
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 033 trials in Peristeri

Open in trial search

Comparison of belantamab mafodotin, bortezomib and dexamethasone versus daratumumab, bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Belantamab Mafodotin
  • Sponsor:Glaxosmithkline Research & Development Limited

Myelofibrosis+1

Recruiting

Study on the Effectiveness and Safety of Selinexor for Patients with Myelofibrosis and Moderate Thrombocytopenia Who Have Not Used JAK Inhibitors

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Aprepitant
  • Sponsor:Karyopharm Therapeutics Inc.

Study of Sacituzumab Tirumotecan and Pembrolizumab for Patients with Triple-Negative Breast Cancer Post-Surgery

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Merck Sharp & Dohme LLC

Thalassaemia beta+2

Recruiting

Study of SP-420 for Patients with Transfusion-Dependent Alpha or Beta Thalassemia

InvestigationalNo placebo
Countries:GreeceGreece
  • Participants:18–64 years
  • Substances:Petadeferitrin
  • Sponsor:Pharmacosmos A/S

Study Comparing Mezigdomide, Bortezomib, and Dexamethasone with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Celgene Corp.

Study on the Effectiveness of Concizumab for Children Under 12 with Hemophilia A or B, With or Without Inhibitors

InvestigationalNo placebo
Countries:GreeceGreece
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Concizumab
  • Sponsor:Novo Nordisk A/S

Study on Carisbamate for Treating Seizures in Children and Adults with Lennox-Gastaut Syndrome

Investigational
Countries:GreeceGreece
  • Participants:0–17 years · 18–64 years
  • Substances:Carisbamate
  • Sponsor:Sk Life Science Inc.

Pouchitis

Recruiting

Study on the Effectiveness and Safety of Vedolizumab for Children with Chronic Pouchitis Using a Drug Combination

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:0–17 years
  • Substances:Amoxicillin Sodium
  • Sponsor:Takeda Development Center Americas Inc.

Study on the Long-Term Safety of Aficamten (CK-3773274) for Patients with Symptomatic Hypertrophic Cardiomyopathy

InvestigationalNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Aficamten
  • Sponsor:Cytokinetics Inc.

Study on the Effectiveness and Safety of Riliprubart Compared to Intravenous Immunoglobulin in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Riliprubart
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study on Apremilast for Treating Oral Ulcers in Children with Behçet's Disease

Investigational
Countries:GreeceGreece
  • Participants:0–17 years
  • Substances:Apremilast
  • Sponsor:Amgen Inc.

Study on the Effects of Iptacopan in Patients with Idiopathic Membranoproliferative Glomerulonephritis (IC-MPGN)

Investigational
Countries:GreeceGreece
  • Participants:0–17 years · 18–64 years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Other cities in Greece

The busiest research cities in the country

All 48 cities in Greece

Clinical research in Peristeri

What the registry says about research in the country

01 Cardiovascular Diseases

In Peristeri, researchers are evaluating a weekly injectable agent for patients with HFpEF or HFmrEF who also have obesity, aiming to lower the combined risk of cardiovascular death and heart‑failure hospitalisations.

  • Composite cardiovascular outcome assessment
  • Weekly dosing strategy
  • Integration with standard of care
  • Focus on heart‑failure subtypes

Both studies are actively recruiting, involve 25 investigators, and seek to improve treatment options for a growing heart‑failure population.

02 Nutritional and Metabolic Diseases

Clinical trials in the city are comparing two formulations of injectable cagrilintide and a placebo, as adjuncts to diet and activity counseling, to achieve meaningful weight loss in participants with excess body weight.

  • Weight‑loss non‑inferiority testing
  • Superiority versus placebo evaluation
  • Adjunct lifestyle intervention
  • Targeting overweight and obesity

The recruiting studies involve a dedicated team of investigators and aim to expand therapeutic options for metabolic health.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.